INTERNATIONAL SOCIETY FOR PHARMACOECONOMICS AND OUTCOMES RESEARCH

ISPOR 17th Annual International Meeting

June 2-6, 2012
Washington, DC, USA

Improving Health Care Efficiency

CALL FOR ABSTRACTS

ABSTRACT SUBMISSION DEADLINE:
JANUARY 19, 2012

EARLY REGISTRATION DEADLINE:
APRIL 17, 2012

MEETING PROGRAM COMMITTEE CHAIR

Sean Tunis, MD, MSc
Founder & Director
Center for Medical Technology Policy
Baltimore, MD, USA

MEETING PROMOTIONAL OPPORTUNITIES

EXHIBIT

Register now! Over 2700 attendees in 2011!

Present your products and services to key outcomes researchers and health care decision-makers in pharmaceutical, medical device & diagnostics, biotechnology industries, clinical practice, government agencies, academia, and health care organizations.

Benefits to Exhibitors:

- Company listing & 1/4 page advertisement in the Program & Schedule of Events
- Company listing & 1/4 page advertisement on the ISPOR website
- One complimentary registration per exhibit booth
- One complimentary set of pre-registrant mailing labels per exhibitor

ADVERTISE

Advertise in the Program & Schedule of Events!

- Company promotion
- Job opportunities
- Publications
- Journals

- Full page, full color cover advertising available
- 1/4, 1/2, and full page, one color advertising available. Prices start from $950.

Advertising Deadline:
April 13, 2012

SPONSOR

Increase your visibility! Give your company increased prominence.

Benefits to Sponsors:

- Sponsorship recognition at the plenary sessions
- Event signage
- Company listing & 1/4 page advertisement in the Program & Schedule of Events
- Company listing & logo advertisement on the ISPOR website
- One complimentary meeting registration
- Preferential exhibit booth location

COMPLETE MEETING INFORMATION AND REGISTRATION AT WWW.ISPOR.ORG

ISPOR 17th Annual International Meeting

June 2-6, 2012 Washington, DC, USA

SHORT COURSE PROGRAM

SATURDAY, JUNE 2, 2012 (ALL DAY COURSES) 8:00AM-5:00PM

Introduction to Pharmacoeconomics
This course demonstrates how to incorporate pharmacoeconomics into study design and data analysis. Participants learn to collect and calculate the costs of different alternatives, determine the economic impact of clinical outcomes, and to identify, track and assign costs to health care resources.

Bayesian Analysis – Overview and Applications
This course provides an overview of the Bayesian approach and its applications to health economics and outcomes research. It covers basic elements of Bayesian statistics, contrasting briefly with classical statistics and introduces available statistical packages. Attendees then apply principles to data analysis problems using WinBUGS.

SATURDAY, JUNE 2, 2012 (MORNING COURSES) 8:00AM-12:00PM

Introduction to Retrospective Database Analysis
This course reviews analytic techniques and best practices to improve causal inference in studies using retrospective databases. Specific topics to be covered include: stratification analysis, multivariable regression, propensity scoring, instrumental variable and structural modeling techniques.

Introduction to Modeling
This course introduces the principles and practice of decision analysis. Participants evaluate the appropriateness of decision analysis, construct simple decision trees, understand basic mechanics of tree evaluation and sensitivity analysis, and acquire skills in the interpretation of a published decision analysis.

Cost-Effectiveness Analysis alongside Clinical Trials
This course presents design, conduct, and reporting of cost-effectiveness analyses alongside clinical trials based in part on The ISPOR RCT-CEA Task Force Report. Analyses guided by an analysis plan and hypotheses, an incremental analysis using an intention to treat approach, characterization of uncertainty and standards for reporting results are presented.

Introduction to Patient-Reported Outcomes
Conceptual, methodological, and practical methods for measuring quality of life, health status and other types of health outcomes are presented. Theoretical frameworks, reliability, validity, responsiveness, methods of administration, respondent and administrative burdens, and issues of analysis and interpretation are discussed.

Elements of Pharmaceutical/Biotech Pricing I – Introduction
This course provides a basic understanding of key terminology and issues involved in pharmaceutical pricing decisions. It covers the tools to build and document product value, the role of pharmacoeconomics and the differences in payment systems that shape pricing decisions.

SATURDAY, JUNE 2, 2012 (AFTERNOON COURSES) 1:00PM-5:00PM

Patient Registries
This course reviews patient registries and their applications in identifying "real world" clinical, safety, and patient-perspective issues. The pros and cons of registry data and how it can support health economics / outcomes research initiatives and decision making are addressed. Registry strategy, design, operations and measures of program success are discussed.

Meta-Analysis and Systematic Reviews in Comparative Effectiveness Research
This course discusses six key areas: 1) comparative effectiveness research; 2) impetus for meta-analysis and systematic reviews; 3) basic steps to perform a quantitative systematic review; 4) statistical methods of combining data; 5) reporting of results; and 6) appraisal and use of meta-analytic reports.

Financial Impact / Cost of Illness
This course describes methods to determine the cost-of-illness of a health condition using a "top-down" or "bottom-up" approach. Participants learn how to estimate the impact of new health care technologies on disease-specific costs from different decision-maker perspectives.

Case Studies in Pharmaceutical/Biotech Pricing II – Advanced
Case studies lead participants through key steps of new product pricing, focusing on the need to thoroughly analyze the business environment, its constraints and opportunities, and the need to integrate pricing, reimbursement and PE strategies for the new product with clinical development and marketing strategies.

Modeling: Design and Structure of a Model
This course reviews Markov models and other techniques, referencing the ISPOR Principles of Good Practice for Decision Analytic Modeling in Health Care Evaluations. Using a series of examples, the course reviews practical steps in developing and using these models.

SUNDAY, JUNE 3, 2012 (ALL DAY COURSE) 8:00AM-5:00PM

Discrete Event Simulation for Economic Analyses
This course provides a basic understanding of the key concepts of discrete event simulation. It focuses on the use of these models to address pharmacoeconomic (and device-related) problems.

SUNDAY, JUNE 3, 2012 (MORNING COURSES) 8:00AM-12:00PM

Bayesian Analysis – Advanced
This course focuses on the use of Markov Chain Monte Carlo methods in conducting policy-relevant outcomes research. Participants engage in hands-on exercises and address certain methodological issues, concluding with a discussion on the role of Bayesian methods in policy-making.

Applications in Using Large Databases
This course reviews 3 databases – GPRD (UK database), GE Centricity electronic medical record (EMR) and Medicare (USA databases). Each database is discussed in-depth including directions on accessing information and how researchers utilize this information.

Patient-Reported Outcomes – Item Response Theory
Applications of IRT have increased considerably because of its utility for instrument development and evaluation, assessment of measurement equivalence, instrument linking, and computerized adaptive testing. This short course discusses the basics of IRT models and applications to improve health outcomes measurement.

Conjoint Analysis
This course introduces the conceptual basis for quantifying decision-maker preferences for medical interventions and the practical design and analytical issues that must be addressed to obtain valid empirical preference estimates.

Utility Measures
This course explores: concepts of health-related quality of life in terms of their differences and similarities; methods used to capture utilities (standard gamble, time trade off and rating scales); and instruments to measure quality of life (EQ-5D, Health Utilities Index and SF-36).

Instrumental Variables in Addressing Selection Bias in Observational Studies
Sample selection models provide a test and correction for the presence of selection bias, enabling an investigator to obtain unbiased estimates of treatment effects. This course discusses various models and their applications, in particular instrumental variables.

Statistical Considerations in Health Economic Evaluations
This course discusses effect of distributional assumptions, analyzing univariate and multivariable analysis data, analyzing censored data, sample size and power calculations, sampling uncertainty, point estimates for variables, net monetary benefit, and confidence intervals for cost-effectiveness ratios.

SUNDAY, JUNE 3, 2012 (AFTERNOON COURSES) 1:00PM-5:00PM

Applications of Statistical Considerations in Health Economic Evaluations
Specific exercises are conducted to illustrate: effect of distributional assumptions, univariate & multivariable analysis of costs, the effect of sample size & power calculations on economic evaluations, point estimates for cost-effectiveness ratios.

Risk-Sharing/Performance-Based Arrangements for Drugs and Other Medical Products
There is significant and growing interest among payers and producers of medical products for arrangements that involve a "pay-for-performance" or "risk-sharing" element. Theory and practice, including incentives and barriers, of these arrangements will be analyzed along with several examples of performance-based schemes from Europe, the United States, and Australia.

Outcomes Research for Medical Devices and Diagnostics
This course presents outcomes research practices specifically tailored for the medical device and diagnostics technology environment. Outcomes research for medical devices and diagnostics is differentiated from other health care interventions. The evidence hierarchy for medical devices and diagnostic procedures is discussed.

Network Meta-analysis for Indirect Treatment Comparison
Network meta-analysis offers a quantitative method of integrating all the data from all the available comparisons. Based in part on two ISPOR Task Force Reports on Indirect Treatment Comparisons, the fundamentals and concepts of network meta-analysis are presented. The material in this course is motivated by instructive and real examples implemented with the WinBUGS package.

Propensity Scores and Observational Studies of Treatment Effect
Faculty discuss how propensity scores can be used to mitigate confounding, the advantages and disadvantages of standard adjustment relative to propensity score-based methods, details of propensity score methodology and risk adjustment models that collapse predictors of outcomes and their use relative to propensity scores.

Establishing the Content Validity of Patient-Reported Outcome (PRO) Instruments
This course focuses on requirements for establishing the content validity of PRO instruments. Content covers definitions of evidence requirements, issues necessitating clarity, and logistical needs for gathering acceptable evidence. Participants will take part in practical exercises as part of the iterative process to determine and establish evidence of content validity for PRO instruments.

Advanced Decision Modeling for Health Economic Evaluations
Key aspects in the development of decision modeling, how models can be made probabilistic to capture parameter uncertainty, and how to analyze and present results are discussed. How results should be interpreted and decisions should be made (including decisions with uncertainty, expected value of perfect information [EVPI], and expected value of sample information [EVSI]) are presented.

For complete short course descriptions go to www.ispor.org

ISPOR 17th Annual International Meeting

June 2-6, 2012 Washington, DC, USA

CALL FOR ABSTRACTS

ABSTRACT SUBMISSION BEGINS: OCTOBER 19, 2011 / ABSTRACT SUBMISSION DEADLINE: JANUARY 19, 2012

SUBMISSION INSTRUCTIONS

All abstracts and proposals MUST be submitted through ISPOR's online abstract submission system by January 19, 2012.
Abstracts accepted for other ISPOR meetings can NOT be submitted and research published or presented at other national or international meetings is discouraged.
SUBMISSION INSTRUCTIONS, EXAMPLES & SPECIFIC EVALUATION CRITERIA AVAILABLE AT www.ispor.org

RESEARCH ABSTRACTS

Outcomes research on all health care interventions (including drugs, devices, behavioral modification programs, surgery, disease prevention, gene therapy, screening, diagnostic procedures and health education) and on all diseases or health disorders are considered. Research abstracts (except for conceptual papers) must be organized by OBJECTIVES, METHODS, RESULTS, CONCLUSIONS. All accepted research abstracts are published in Value in Health as submitted. Accepted research is presented as a 15 minute podium presentation or poster presentation (with a poster author discussion hour). Abstracts are evaluated on the quality of the study (or concept) and quality of the abstract presentation.
Research topics include: Clinical Outcomes Studies, Cost Outcomes Studies, Patient-Reported Outcomes & Preference-based Studies, Health Care Use & Policy Studies, Research on Methods, Conceptual Papers. See the ISPOR website for research subtopics, diseases and health care treatments.

HEALTH CARE DECISION-MAKER CASE STUDY ABSTRACTS

Health care decision-maker case study abstracts must describe an organization's attempt to integrate cost or outcomes research information into their health care organization's processes and procedures. Case Study abstracts must be organized: ORGANIZATION, PROBLEM OR ISSUE ADDRESSED, GOALS, OUTCOMES RESEARCH USED IN THE DECISION, RESULTS, LESSONS LEARNED. Negative as well as positive results are encouraged. Accepted case studies are presented as a 20 minute podium presentation or poster presentation (with a poster author discussion hour). THE PRESENTER MUST BE A HEALTH CARE DECISION-MAKER.

ISSUE PANEL PROPOSALS

Issue panel proposals should show real debate on new or controversial issues in health economics and outcomes research or real debate on the use of outcomes research in health care decision-making. Issue panel proposals must be organized MODERATOR, PANELISTS, ISSUE, OVERVIEW. An accepted issue panel is one hour in duration with a moderator and 2-3 panelists representing different organizations. Panelists should present distinct views about the topic.
Issue Panel topics are: Clinical Outcomes Research Issues, Economic Outcomes Research Issues, Patient-Reported Outcomes Research Issues, Health Policy Development Using Outcomes Research Issues.

WORKSHOP PROPOSALS

Workshop proposals should show novel and innovative experiences in the conduct of outcomes research (including, but not limited to, experiences with conjoint analysis, large database analysis, modeling, observational studies, record review, surveys, sensitivity analysis and patient registries) or novel and innovative experiences in the use of outcomes research (clinical, economic, or patient-reported/preference-based outcomes) in health care policy development. Workshop proposals must be organized by DISCUSSION LEADERS, PURPOSE, DESCRIPTION. Accepted workshops are one hour in duration with a minimum of 2 and maximum of 4 discussion leaders (more than one organization must be represented). An audience interactive element must be included in the proposal and during the workshop.
Workshop topics include: Clinical Outcomes Research, Economic Outcomes Research, Patient-Reported Outcomes & Preference-based Research, Use of Real World Data, Health Policy Development Using Outcomes Research. See the ISPOR website for workshop subtopics.

PRELIMINARY PROGRAM

Over 2700 attendees in 2011!

MONDAY, JUNE 4: 8:00AM – 8:30PM

FIRST PLENARY SESSION: IMPROVING ACCESS & EFFICIENCY TO NEW DRUGS: SHOULD THE FDA / EMA BE ASKING 'DOES IT WORK BETTER' VERSUS 'DOES IT WORK'?

Drug regulatory bodies (FDA/EMA) are to assure that the drug does more good than harm in its intended users (i.e. does it work?). Whereas for government agencies or organizations reimbursing drugs (payers), the question is: 'Is the new drug better compared to existing treatments and, if so, at what cost?' Regulatory and reimbursement decisions are determined almost simultaneously, and with almost the same drug information and uncertainties, but by different organizations. To improve efficiency of payer decision making and access to the new drugs, should the question for the regulatory agencies be: 'does it work better' versus 'does it work'? During this plenary session, 'does the drug work better' versus 'does the drug work' as the regulatory question will be debated from the perspective of the regulatory body, a pharmaceutical manufacturer and a payer.

**** 20 Research Podium Presentations * 14 Workshops * 6 ISPOR Group Forums * 5 Issue Panels * Exhibits * 350 Research Poster Presentations – Session I***

TUESDAY, JUNE 5: 8:00AM – 8:00PM

SECOND PLENARY SESSION: HEALTH REFORM IN THE UNITED STATES: WILL STATE HEALTH INSURANCE EXCHANGES IMPROVE THE EFFICIENCY AND AFFORDABILITY OF HEALTH CARE?

In the US Patient Protection and Affordable Care Act (ACA) of 2010, States are required by 2014 to create health insurance exchanges designed to help individuals and small businesses to 'shop for' and purchase health insurance – a gateway for about 29 million US citizens to access health coverage. During this session, quality and choice of plans, affordability of coverage, and ease of enrollment for three State health insurance exchanges – the Oregon Health Plan, the Massachusetts Connector, and the Utah Health Exchange will be presented. Lessons learned from each will be discussed.

**** 40 Research Podium Presentations * 14 Workshops * 5 Issue Panels * Exhibits * 350 Research Poster Presentations – Session II * Evening Social Event***

WEDNESDAY, JUNE 6: 8:00AM – 4:00PM

THIRD PLENARY SESSION: PERFORMANCE-BASED RISK-SHARING ARRANGEMENTS: GOOD RESEARCH PRACTICES FOR DESIGN, IMPLEMENTATION AND EVALUATION

There is growing interest among the payers and producers of new drugs and therapeutic devices for arrangements that involve a 'pay-for-performance' or 'risk-sharing' element. In these payment schemes, the product's performance is tracked in a defined patient population over a specified period of time. The level of reimbursement is tied by formula to the outcomes achieved. During this plenary session, recommendations in the Performance-Based Risk-Sharing Arrangements Good Research Practices for Design, Implementation and Evaluation: An ISPOR Task Force Report will be presented. This Report builds on the Banff Consensus Principles with respect to design, builds on the NICE Patient Access Schemes with respect to implementation, and defines good practices for assessing the overall performance of a scheme.

****10 Workshops * 5 Issue Panels * Exhibits * 350 Research Poster Presentations – Session III***

ISPOR 17th Annual International Meeting

June 2-6, 2012 Washington, DC, USA

NAME _____ DEGREES _____ **Member ID#** _____

POSITION _____ ORGANIZATION _____

MAILING ADDRESS _____

CITY _____ STATE _____ ZIP _____ COUNTRY _____

TELEPHONE _____ FAX _____ EMAIL _____

SHORT COURSES

SATURDAY, JUNE 2, 2012

All Day Courses 8:00 AM – 5:00 PM

❑ Introduction to Pharmacoeconomics
❑ Bayesian Analysis – Overview and Applications

Morning Courses 8:00 AM – 12:00 PM

❑ Introduction to Retrospective Database Analysis
❑ Introduction to Modeling
❑ Cost-Effectiveness Analysis alongside Clinical Trials
❑ Introduction to Patient-Reported Outcomes
❑ Elements of Pharmaceutical/Biotech Pricing I – Introduction

Afternoon Courses 1:00 PM – 5:00 PM

❑ Patient Registries
❑ Meta-Analysis and Systematic Reviews in Comparative Effectiveness Research
❑ Financial Impact / Cost of Illness
❑ Case Studies in Pharmaceutical/Biotech Pricing II – Advanced
❑ Modeling: Design and Structure of a Model

SUNDAY, JUNE 3, 2012

All Day Course 8:00 AM – 5:00 PM

❑ Discrete Event Simulation for Economic Analyses

Morning Courses 8:00 AM – 12:00 PM

❑ Bayesian Analysis – Advanced
❑ Applications in Using Large Databases
❑ Patient-Reported Outcomes – Item Response Theory
❑ Conjoint Analysis
❑ Utility Measures
❑ Instrumental Variables in Addressing Selection Bias in Observational Studies
❑ Statistical Considerations in Health Economic Evaluations

Afternoon Courses 1:00 PM – 5:00 PM

❑ Applications of Statistical Considerations in Health Economic Evaluations
❑ Risk-Sharing/Performance-Based Arrangements for Drugs and Other Medical Products
❑ Outcomes Research for Medical Devices and Diagnostics
❑ Network Meta-analysis for Indirect Treatment Comparison
❑ Propensity Scores and Observational Studies of Treatment Effect
❑ Establishing the Content Validity of Patient-Reported Outcome (PRO) Instruments
❑ Advanced Decision Modeling for Health Economic Evaluations

HALF DAY SHORT COURSE FEES

Registration Before April 17, 2012: REGULAR FEE: ❍ US$150 / STUDENT FEE: ❍ US$75
Registration After April 17, 2012: REGULAR FEE: ❍ US$200 / STUDENT FEE: ❍ US$100

ALL DAY SHORT COURSE FEES

Registration Before April 17, 2012: REGULAR FEE: ❍ US$300 / STUDENT FEE: ❍ US$150
Registration After April 17, 2012: REGULAR FEE: ❍ US$400 / STUDENT FEE: ❍ US$200

ISPOR MEETING REGISTRATION

	ISPOR Member	Non-Member*
Standard		
Registration Before April 17, 2012	❍ US$650	❍ US$790
Registration After April 17, 2012	❍ US$750	❍ US$890
Clinical Practitioners (Clinical Practice, Hospital)		
Registration Before April 17, 2012	❍ US$450	❍ US$590
Registration After April 17, 2012	❍ US$550	❍ US$690
Full-Time Government and Academia		
Registration Before April 17, 2012	❍ US$350	❍ US$490
Registration After April 17, 2012	❍ US$450	❍ US$590
Full-Time Students (must provide current enrollment documentation)		
Registration Before April 17, 2012	❍ US$150	❍ US$185
Registration After April 17, 2012	❍ US$200	❍ US$235
One Day Registration (per day)** (One Day registrations cannot be combined)		
__ June 4 __ June 5 __ June 6	❍ US$350	❍ US$400
Continuing Education Accreditation	❍ US$100	❍ US$100

ISPOR Social Event:
Tuesday, June 5, 8:00pm-11:30pm ❍ US$50 ❍ US$25 student

REGISTRATION FEES

	QTY	FEE	TOTAL
Short Course All Day Registration			
Short Course Half Day Registration			
Meeting Registration			
Continuing Education Accreditation			
ISPOR Social Event			

TOTAL REGISTRATION FEE: _____

PAYMENT INFORMATION

Please enclose a check payable in US dollars to: International Society for Pharmacoeconomics and Outcomes Research or ISPOR and send to the ISPOR address given below or charge to: ❍ VISA ❍ MasterCard ❍ American Express Account Number: _____ Expiration Date: _____

Name: _____ Authorized Signature: _____

Mail Details: If not paying by credit card online, send registration form and payment to: International Society for Pharmacoeconomics and Outcomes Research, 3100 Princeton Pike, Building 3 Suite E, Lawrenceville, New Jersey 08648, USA Tel: 1-609-219-0773
Fax: 1-609-219-0774 • E-Mail: info@ispor.org • Internet: www.ispor.org

Payment Details: Payment may be made by check, travelers check, bank transfer (there is a USD $40 charge) or credit card. VISA, MasterCard, or American Express will be charged in US dollars. Signature, account number and expiration date must be included. Non-US checks written in US$ on banks with a US counterpart are at no charge. For Non-US checks written in US$ on banks with NO US counterpart there is USD $25 charge. Phone charges will NOT be accepted.

If payment is being made by your company, please make sure your name is indicated on the check stub or correspondence. For bank transfers, please designate the registration name and/or registration number.

*** Membership Details:** If ISPOR cannot verify your current membership, you will be charged the non-member registration rate. When you register as a non-member, you receive an ISPOR membership which includes a one year online subscription to *Value in Health* - The Journal of the International Society for Pharmacoeconomics and Outcomes Research.

**** One Day Registration Details:** One day registration does not include ISPOR membership benefits and cannot be combined.

Cancellation Details: Cancellation fee before April 17, 2012 is US $100.
No refunds given after April 17, 2012.

FOR MORE INFORMATION: www.ispor.org